BTR Capital Management Inc. reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 138,454 shares of the company’s stock after selling 279 shares during the period. Merck & Co., Inc. comprises 2.2% of BTR Capital Management Inc.’s holdings, making the stock its 15th largest position. BTR Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $11,655,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of MRK. Fox Run Management L.L.C. lifted its position in Merck & Co., Inc. by 4.4% during the third quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock worth $238,000 after buying an additional 118 shares in the last quarter. First Command Bank increased its stake in Merck & Co., Inc. by 1.4% during the third quarter. First Command Bank now owns 8,599 shares of the company’s stock worth $724,000 after acquiring an additional 118 shares during the last quarter. Allworth Financial LP increased its stake in Merck & Co., Inc. by 1.9% during the third quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock worth $528,000 after acquiring an additional 119 shares during the last quarter. Stillwater Investment Management LLC increased its stake in Merck & Co., Inc. by 2.6% during the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after acquiring an additional 120 shares during the last quarter. Finally, Southeast Asset Advisors Inc. increased its stake in Merck & Co., Inc. by 2.3% during the second quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock worth $449,000 after acquiring an additional 120 shares during the last quarter. 75.02% of the stock is currently owned by institutional investors.
In related news, EVP Richard R. Deluca sold 6,427 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.
Shares of NYSE MRK traded down $0.36 during trading on Monday, reaching $84.32. The stock had a trading volume of 504,486 shares, compared to its average volume of 7,689,117. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.35. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The business’s 50-day moving average price is $84.37 and its 200-day moving average price is $82.31. The company has a market cap of $214.56 billion, a P/E ratio of 19.43, a PEG ratio of 1.96 and a beta of 0.53.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. During the same period in the previous year, the firm posted $1.06 earnings per share. The company’s revenue was up 12.4% on a year-over-year basis. Analysts forecast that Merck & Co., Inc. will post 4.91 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were paid a $0.55 dividend. The ex-dividend date was Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.61%. Merck & Co., Inc.’s payout ratio is presently 50.69%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.